Book by None
Die Inhaltsangabe kann sich auf eine andere Ausgabe dieses Titels beziehen.
A sophisticated investor's practical tool kit for
analyzing the science, business, opportunities, and risks in the century's most promising industry
The world is entering a biotechnology boom-but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, San Francisco Chronicle science and technology columnist Tom Abate, one of the top objective authorities on biotech, gives investors the analytical foundation to understand the science, finances, time horizon, and technological and commercial potential of this burgeoning industry.
In "The Biotech Investor," Abate provides sophisticated business analysis, guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He explains how breaking news, medical conferences, U.S. Food and Drug Administration approvals, and the patent process affect investing strategies. Finally, he looks beyond medicine to review the financial opportunities presented by biotechnology advances in everything from agriculture to jean manufacturing, and shows investors how to identify "coattail" industries such as instrumentation and software development that will benefit from biotech successes.
The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.
Award-winning biotechnology, technology, and health care reporter Tom Abate writes the weekly BioScope column for the "San Francisco Chronicle." He lives in San Leandro, California.
„Über diesen Titel“ kann sich auf eine andere Ausgabe dieses Titels beziehen.